Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABSW) Other Non-Current Liabilities (2021 - 2025)

SAB Biotherapeutics' Other Non-Current Liabilities history spans 5 years, with the latest figure at $5.6 million for Q4 2025.

  • For Q4 2025, Other Non-Current Liabilities fell 11.8% year-over-year to $5.6 million; the TTM value through Dec 2025 reached $5.6 million, down 11.8%, while the annual FY2025 figure was $5.6 million, 11.8% down from the prior year.
  • Other Non-Current Liabilities reached $5.6 million in Q4 2025 per SABSW's latest filing, up from $2.4 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $11.8 million in Q4 2023 to a low of $8344.0 in Q1 2023.
  • Average Other Non-Current Liabilities over 5 years is $3.8 million, with a median of $3.2 million recorded in 2021.
  • Peak YoY movement for Other Non-Current Liabilities: tumbled 99.71% in 2023, then skyrocketed 75475.46% in 2024.
  • A 5-year view of Other Non-Current Liabilities shows it stood at $10.7 million in 2021, then crashed by 97.01% to $320930.0 in 2022, then surged by 3568.79% to $11.8 million in 2023, then crashed by 45.74% to $6.4 million in 2024, then decreased by 11.8% to $5.6 million in 2025.
  • Per Business Quant, the three most recent readings for SABSW's Other Non-Current Liabilities are $5.6 million (Q4 2025), $2.4 million (Q3 2025), and $2.0 million (Q2 2025).